-  INCLUSION CRITERIA:

          -  Participants must have histologically or cytologically confirmed diagnosis of a
             metastatic non-prostate genitourinary tumor.

          -  Participants must have metastatic disease defined as new or progressive lesions on
             cross-sectional imaging. Radiological evaluation should occur within 21 days prior to
             enrollment.

          -  Participants must have evaluable or measurable disease.

          -  Participants in Arms 2 and 3 must have at least one site of disease that is amenable
             to irradiation (irradiation of up to 4 different sites is permitted)

          -  Participants must have at least one measurable site of disease that will not be
             irradiated.

          -  Participants may have been previously treated with cytotoxic chemotherapy regimen or
             targeted agent. Partaicipants may have received any number of prior cytotoxic agents.

          -  Participants may have been previously treated with radiation therapy. However,
             re-irradiation of a previously irradiated site is not permitted unless explicitly
             discussed with protocol PI and treating radiation oncologist.

          -  Participants may have had prior immunomodulating therapy including therapy with a
             checkpoint inhibitor but excluding prior treatment with M7824 and/or M9241.

          -  Pre-treatment tissue availability (collected less than or equal to 1 year) for PD-L1
             expression testing is mandatory for enrollment. If tissue is determined to be of
             insufficient/unsuitable quality/quantity, a pre-treatment biopsy prior to initiation
             of study therapy will be required.

          -  Male and female participants who are at least 18 years of age on the day of signing
             the informed consent will be enrolled in the study.

          -  ECOG performance status less than or equal to 2 (Karnofsky greater than or equal to
             60%)

          -  Patients must have adequate organ and marrow function as defined below:

               -  leukocytes greater than or equal to 2500mcL

               -  absolute neutrophil count greater than or equal to 1500/mcL

               -  platelets greater than or equal to 100,000/mcL

               -  AST(SGOT)/ALT(SGPT) less than or equal to 1.5 X institutional upper limit of
                  normal

               -  Hgb greater than or equal to 9g/dL (pRBC transfusions are allowed to achieve
                  acceptable Hgb)

          -  Participants may have mild to moderate hepatic impairment with total bilirubin less
             than or equal to 3.0 (SqrRoot) ULN.

          -  For Participants with liver involvement in their tumor, we allow the following: AST
             less than or equal to 5.0 (SqrRoot) ULN, ALT less than or equal to 5.0 (SqrRoot) ULN,
             and bilirubin less than or equal to 3.0 (SqrRoot) ULN.

          -  Calculated Creatinine clearance greater than or equal to 20 mL/min (using either
             CKD-EPY equation)

          -  The effects of M7824 and/or M9241 on the developing human fetus are unknown. For this
             reason, women of child-bearing potential and men must agree to use strict and
             effective contraception during treatment and for at least 65 days for women and 125
             days for men after the last dose of M7824 administration. Should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately.

          -  HIV-positive participants are eligible if on stable dose of highly active
             antiretroviral therapy (HAART), CD4 counts are greater than 350 cells/mm3 and viral
             load is undetectable.

          -  Participants with previously treated brain or CNS metastases are eligible provided
             that the subject has recovered from any acute effects of radiotherapy and is not
             requiring steroids, and any whole brain radiation therapy was completed at least 2
             weeks prior to M7824 administration, or any stereotactic radiosurgery was completed at
             least 2 weeks prior to M7824 administration.

          -  HBV positive Participants are eligible-they must have been treated and on a stable
             dose of antivirals [eg, entecavir, tenofovir, or lamivudine; (adefovir or interferon
             are not allowed)] at study entry and with planned monitoring and management according
             to appropriate labeling guidance.

          -  HCV positive Participants are eligible if participants are on active HCV therapy at
             study entry and must be on a stable dose without documented clinically significant
             impaired liver function test or hematologic abnormalities and with planned monitoring
             and management according to appropriate labeling guidance.

          -  Ability to understand and the willingness to sign a written informed consent document.

        EXCLUSION CRITERIA:

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to M7824 and/or M9241 investigational agents used in the study.

          -  Uncontrolled intercurrent illness including, but not limited to, symptomatic
             congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric
             illness/social situations that would limit compliance with study requirements.
             Patients with a history of bleeding diathesis or recent clinically significant
             bleeding events considered by the Investigator as high risk for investigational drug
             treatment are also excluded with the exception of hematuria.

          -  Subjects unwilling to accept blood products as medically indicated

          -  Pregnant women are excluded from this study because M7824 and/or M9241 are agents with
             the potential for teratogenic or abortifacient effects. Because there is an unknown
             but potential risk for adverse events in nursing infants secondary to treatment of the
             mother with M7824 and/or M9241, breastfeeding should be discontinued if the mother is
             treated with these agents.

          -  Participants with any active or recent history of a known or suspected autoimmune
             disease or recent history of a syndrome that required treatment with either systemic
             corticosteroids (>10 mg daily prednisone equivalent) or immunosuppressive medications.
             Inhaled steroids and adrenal replacement steroid doses up to 10 mg daily prednisone
             equivalents are permitted in the absence of active autoimmune disease.

          -  Participants with any active or recent history of inflammatory bowel disease, active
             lupus or scleroderma or other medical conditions (i.e pneumonits with planned SBRT to
             lung lesion) or genetic radiosensitivity syndromes will be excluded from the study
             unless deemed eligible by Principal Investigator because these diseases make the
             subject unsafe or ineligible for radiation therapy with SBRT.

          -  Patients with a currently active second malignancy other than non-melanoma skin
             cancers or cervical carcinoma in situ or incidental organ-confined prostate cancer
             found on cystoprostatectomy (provided that the following criteria are met: Stage
             T2N0M0 or lower; Gleason score <= 3+4, PSA undetectable). Patients are not considered
             to have a currently active malignancy if they have completed therapy and are free of
             disease for >= 2 years and currently do not require systemic therapy

          -  Participants having tumor lesion(s) in the liver or chest which are 10 cm or larger.